A phase 3 trial evaluating sotatercept-csrk (Winrevair™) in adults with pulmonary arterial hypertension (PAH; World Health Organization Group 1) ...
The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two ...
Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary ...
SAN DIEGO - Gossamer Bio, Inc. (NASDAQ:GOSS), a biopharmaceutical company in the clinical stage with a market capitalization of $225 million, has shared new research findings on its drug candidate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback